Emergent BioSolutions Inc. (EBS)
NYSE
Key stats Fiscal year 2025
Income statement
- Revenue
- 742,900,000 -28.8%
- Net income
- 52,600,000
- Operating income
- 100,100,000
- Earnings per share
- 0.98
- R&D expense
- 53,200,000
Growth and profitability
- Operating margin
- 13.47
- Net margin
- 7.08
- Return on equity
- 10.07
- Return on assets
- 3.99
- Free cash flow margin
- 21.11
Balance sheet
- Total assets
- 1,318,600,000
- Total liabilities
- 796,000,000
- Shareholders' equity
- 522,600,000
- Cash and equivalents
- 205,400,000
- Debt
- 589,700,000
- Net debt
- 384,300,000
- Current ratio
- 5.01
- Debt to equity
- 1.13
Cash flow and ratios
- Operating cash flow
- 170,600,000
- Free cash flow
- 156,800,000
Shareholder returns
- Share buybacks
- 24,900,000
- Shares outstanding
- 51,415,182
- Book value per share
- 10.16
Company information
- Headquarters
- Gaithersburg, MD
- Exchange
- NYSE
- Fiscal year end
- 12-31
- Industry (SEC)
- Pharmaceutical Preparations
Fiscal year end: · Source: SEC EDGAR
Emergent BioSolutions Inc. trades on NYSE under the ticker symbol EBS. This page brings together its price chart, company profile, key financial figures and technical indicators.